Compare EEIQ & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEIQ | HCWB |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 5.0M |
| IPO Year | 2019 | 2021 |
| Metric | EEIQ | HCWB |
|---|---|---|
| Price | $5.37 | $1.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 14.8K | ★ 819.2K |
| Earning Date | 01-28-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.25 |
| 52 Week High | $12.70 | $5.61 |
| Indicator | EEIQ | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 80.29 | 36.26 |
| Support Level | $2.31 | $0.97 |
| Resistance Level | $5.36 | $3.90 |
| Average True Range (ATR) | 0.34 | 0.28 |
| MACD | 0.13 | -0.02 |
| Stochastic Oscillator | 85.31 | 10.60 |
EpicQuest Education Group International Ltd provides comprehensive education solutions for domestic and international students interested in university and college degree programs in the U.S, Canada, and the UK. In addition, the company has a recruiting relationship with the regional campuses of Miami University of Ohio, where it maintains residential facilities, a full-service cafeteria, recreational facilities, shuttle buses, and an office for the regional campuses that provides study abroad and post-study services for its students; these facilities are not owned, maintained, operated or are part of Miami University. The Company's revenue is derived from foreign education programs, university education programs and student accommodation services.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.